Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT06483672
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Adenocarcinoma of Lung Metastatic to Brain

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    Furmonertinib 80mg, once daily, orally
  • Anlotinib — DRUG
    Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally

Study Details

The goal of this clinical trial is to learn if furmonertinib plus anlotinib works to treat participants with lung adenocarcinoma with EGFR mutations and brain metastases. It will also learn about the safety of furmonertinib plus anlotinib. The main questions it aims to answer are: * Does furmonertinib plus anlotinib increase the number of participants who has a significant tumor shrinkage? * What medical problems do participants have when taking furmonertinib plus anlotinib? Researchers will evaluate the safety and efficacy of furmonertinib plus anlotinib. Participants will: * Take furmonertinib(every day) and anlotinib(two weeks on and one week off) * Visit the clinic once every 3 weeks for checkups and tests. * Keep a diary of their symptoms.

Key Dates

Start date
Jul 31, 2024
Status verified
Jun 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2027

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib combine with anlotinib
    Furmonertinib 80mg, once daily, orally Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally

Primary Outcome Measure

Central Nervous System Objective Response Rate (CNS ORR) [ Time Frame: Approximately 12 weeks after the last patient begin study treatment ]

Central Contacts